Utilization of remimazolam during cesarean section for a parturient with prior birth trauma

The placement of neuraxial anesthesia, and cesarean section itself, can be a source of significant anxiety and discomfort. While anxiolysis may improve patient comfort, the use of benzodiazepines is often limited by concerns about maternal respiratory depression, neonatal sedation, and hypotonia. Remimazolam (ByFavo™ in the US) is a novel, ultra-short-acting benzodiazepine characterized by a rapid onset, predictable recovery, and favorable hemodynamic profile. As a category of medications, benzodiazepines do cross the placenta and may cause respiratory depression, hypotension, and sedation in neonates. However, the novel structure and rapid metabolism of remimazolam is responsible for its clinically decreased recovery time and makes it an ideal agent for procedural anxiolysis for obstetric procedures. Remimazolam was approved for procedural sedation in the US in 2020 for adult populations; however, its use in obstetric anesthesia remains off-label and largely underutilized due to limited safety data. Despite this, it has been described in case reports and explored for potential benefits such as the prevention of nausea and vomiting during cesarean delivery. This case illustrates a novel application of remimazolam in a sensitive population, highlighting its potential as a safe and effective agent for anxiolysis in the obstetric setting.